Basket 05 — High Purity Dexamethasone
Dexamethasone
High Purity Basket
High-purity steroid basket for regulated-market quality positioning. BJPPL Vapi product basket.
Portfolio Products
Dexamethasone Base
API — Oral / Injectable
Free base form; used in oral tablets, eye drops and topical preparations
Dexamethasone Sodium Phosphate
API — Injectable
Water-soluble salt; preferred for parenteral formulations and infusions
The Glucocorticoid Standard
"25 times more potent than cortisol — with negligible mineralocorticoid effect. The benchmark synthetic glucocorticoid."
×25
Anti-inflammatory potency vs. cortisol
36–54 hr
Biological half-life (extended duration)
RECOVERY
2020 landmark trial — ICU mortality reduction in COVID-19
Dexamethasone is among the most precisely characterised glucocorticoids in medicine. Its potency — approximately 25 times that of cortisol — and its minimal mineralocorticoid activity make it the agent of choice where anti-inflammatory or immunosuppressant action is required without fluid retention. From cerebral oedema to COVID-19 critical care (RECOVERY trial), from nausea prophylaxis in chemotherapy to neonatal lung maturation, dexamethasone's clinical footprint spans more indications than almost any other single molecule.
The quality differentiation in dexamethasone manufacturing is not trivial. Impurity profiles — particularly related process impurities and degradation products — are scrutinised intensely by regulated-market pharmacopoeias (USP, BP, EP). High-purity dexamethasone API, manufactured to GMP standards with full analytical characterisation, commands a distinct position against commodity-grade supply. The BJPPL Vapi facility brings that regulatory-grade manufacturing discipline to both base and sodium phosphate salt forms.
The sodium phosphate salt offers the water solubility required for intravenous and intramuscular injection — the route that matters in acute care. Its use in corticosteroid infusion protocols, dexamethasone suppression tests, and anti-emetic prophylaxis keeps it in constant demand across hospital pharmacy procurement channels. For manufacturers seeking a regulated-market dexamethasone supply partnership, both forms together provide a complete offering.
Clinical Footprint
Indications spanning acute and chronic care
Cerebral Oedema
Established first-line IV corticosteroid
Anti-emesis (Chemotherapy)
Pre-treatment prophylaxis protocol
COVID-19 Critical Care
RECOVERY trial — mortality reduction proven
Neonatal Lung Maturation
Antenatal corticosteroid therapy
Inflammatory Conditions
Arthritis, dermatitis, IBD, allergy
Dexamethasone Suppression Test
Cushing syndrome diagnostic standard
Quality Positioning
Both Dexamethasone Base and Dexamethasone Sodium Phosphate are manufactured at BJPPL Vapi to regulated-market GMP standards. Impurity profiling, analytical characterisation and pharmacopoeial compliance (USP / BP / EP) are integral to the supply offering — not optional add-ons.